stop_circleTerminated/Withdrawn

Chronic Kidney Disease, Diabetic Kidney Disease

A trial to learn more about how BAY2327949 works and how safe it is in patients whose kidneys are damaged due to high blood sugar levels or high blood pressures, and with a further disease of the heart or the blood vessels.

Trial purpose

In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.

High blood pressure is a common condition that can cause damage to the blood vessels and heart if it is untreated. High blood pressure is also known as hypertension.

Patients with type 2 diabetes (T2D) or high blood pressure are at a higher risk of having chronic kidney disease (CKD). In people with CKD, the kidneys become damaged and do not work as they should. Over time, the function of the kidney declines more, and this can lead to the requirement for dialysis or kidney transplantation. Most people with CKD are also at risk of heart conditions, such as heart attack or stroke.

In this trial, the researchers want to learn if BAY2327949 reduces the amount of protein in the participants’ urine. Protein in the urine is one of the signs of CKD. The researchers will compare the effects of BAY2327949 to a placebo. A placebo looks like the study drug but does not have any medicine in it. BAY2327949 is assumed to increase the blood flow through the kidneys, which may slow down the worsening of the disease. The researchers will use a placebo to learn if the changes seen in the participants are due to BAY2327949 or if the results could be due to chance.

This trial will include about 120 men and women over the age of 45 who have CKD. The participants will have T2D or high blood pressure, and a further disease of the heart or blood vessels.

During the trial, the participants will take either BAY2327949 or a placebo once a day for 28 days. The participants will visit their trial site about 9 times during the trial, and need to provide urine samples to check the participants’ CKD symptoms. At the visits, the doctors will ask them if they have any health problems. They will also take blood samples to perform laboratory assessments.

Key Participants Requirements

Sex

All

Age

45 - N/A

Trial summary

Enrollment Goal
0
Trial Dates
May 2021 - May 2022
Phase
Phase 2
Could I Receive a placebo
Yes
Products
BAY2327949
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Withdrawn
ÖbackaklinikenHärnösand, 871 31, Sweden
Not yet recruiting
ProbarELund, 222 22, Sweden
Withdrawn
ProbarEStockholm, 111 37, Sweden
Not yet recruiting
Center For Diabetes, Academic Specialist CenterStockholm, 113 65, Sweden
Not yet recruiting
Akademiska SjukhusetUppsala, 751 85, Sweden
Withdrawn
Kliniska vetenskaper, DSDanderyd, 182 57, Sweden
Not yet recruiting
Carlanderska SjukhusetGöteborg, 405 45, Sweden
Not yet recruiting
Dalecarlia Clinical ResearchRättvik, 795 30, Sweden
Not yet recruiting
Regionshospitalet HerningHerning, 7400, Denmark
Not yet recruiting
Sydvestjysk Sygehus EsbjergEsbjerg, 6700, Denmark
Not yet recruiting
Aarhus Universitetshospital, SkejbyAarhus N, 8200, Denmark
Not yet recruiting
Odense UniversitetshospitalOdense C, DK-5000, Denmark
Withdrawn
Hvidovre HospitalHvidovre, 2650, Denmark
Not yet recruiting
Hvidovre HospitalHvidovre, 2650, Denmark
Not yet recruiting
Nordsjællands HospitalHillerød, 3400, Denmark
Not yet recruiting
Sykehuset Innlandet HF HamarHamar, 2326, Norway
Not yet recruiting
AKTIMED Helse ASHamar, 2317, Norway
Not yet recruiting
Oslo Universitetssykehus HF, RikshospitaletOslo, 0586, Norway
Withdrawn
Spesialistsenteret Pilestredet ParkOslo, 0176, Norway
Not yet recruiting
Skedsmo Medisinske SenterSkedsmokorset, 2020, Norway
Withdrawn
Oslo Universitetssykehus HF, RikshospitaletOslo, 0372, Norway
Not yet recruiting
Stavanger Helseforskning ASStavanger, 4011, Norway
Not yet recruiting
St. Olavs Hospital HFTrondheim, 7006, Norway
Not yet recruiting
Medizinische Universität GrazGraz, 8036, Austria
Not yet recruiting
Konventhospital Barmherzige Brüder LinzLinz, 4021, Austria
Not yet recruiting
Zentrum f. klinische Studien Dr. Hanusch GmbHWien, 1060, Austria
Not yet recruiting
Universitätsklinikum St. PöltenSt. Pölten, 3100, Austria
Not yet recruiting
Landeskrankenhaus FeldkirchFeldkirch, 6807, Austria
Not yet recruiting
Universitätsklinikum AKH WienWien, 1090, Austria
Not yet recruiting
Klinik HietzingWien, 1130, Austria
Not yet recruiting
Kantonsspital St. GallenSt. Gallen, 9007, Switzerland
Not yet recruiting
Inselspital Universitätsspital BernBern, 3010, Switzerland
Not yet recruiting
Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, 1011, Switzerland
Not yet recruiting
Turun yliopistollinen keskussairaala, kantasairaalaTurku, 20520, Finland
Not yet recruiting
Health Step Finland OyKuopio, 70100, Finland
Not yet recruiting
Oulun yliopistollinen sairaalaOulu, 90220, Finland
Not yet recruiting
Seinäjoen keskussairaalaSeinäjoki, FIN 60220, Finland
Not yet recruiting
Päijät-Hämeen keskussairaalaLahti, 15850, Finland
Not yet recruiting
Albert Schweitzer Ziekenhuis, locatie ZwijndrechtZWIJNDRECHT, 3331 LZ, Netherlands
Not yet recruiting
Maxima Medisch Centrum, locatie EindhovenEINDHOVEN, 5600 PD, Netherlands
Not yet recruiting
Albert Schweitzer Ziekenhuis, Locatie DordwijkDORDRECHT, 3318 AT, Netherlands
Not yet recruiting
Academisch Medisch Centrum (AMC)AMSTERDAM, 1105 AZ, Netherlands

Primary Outcome

  • Change from baseline in urine albumin-to-creatinine ratio (UACR) to the end of treatment (Visit 6)
    date_rangeTime Frame:
    Baseline and Visit 6 (28 days)

Secondary Outcome

  • Frequency of treatment-emergent adverse events (TEAEs)
    date_rangeTime Frame:
    From the first treatment with the study intervention until 7 days after the last dose, up to 5 weeks

Trial design

A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of BAY 2327949 in patients with chronic kidney disease (eGFR range from 25 to 60 mL/min/1.73 m²) due to type 2 diabetes or hypertension and at least one cardiovascular comorbidity
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
N/A
Assignment
Parallel Assignment
Trial Arms
2